|
Leukopaks contain up to 10 billion PBMCs from the same donor; that’s the equivalent of 100 collections of 100 mL each from most patients. Such reduced variability makes leukopaks the preferred choice for assay validation, process development, and identifying rare immune cells. But procuring clinically annotated human leukapheresis products can be challenging, particularly those from patients with confirmed disease diagnosis.
Sanguine Biosciences will soon start offering cryopreserved leukopaks from donors with autoimmune diseases, including IBD, lupus, atopic dermatitis, and MS. These products will be collected from donors among our nationwide network of 60,000+ research-ready patients at CLIA/CAP certified partner institutes.
Learn more about how Sanguine leukopaks can accelerate your research, and ask us about prospective collection of other sample types concurrently with PBMCs.
|
|
